Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement

company stock symbols can be found in the stock report located on the last two pages of this issue

the primary endpoint was met in arm C with a complete early viral response of 64%, compared to 30% in the control arm 4/30/13 Vertex Pharmaceuticals Inc. (Cambridge, Mass.) ALS-2200 VX-135 Hepatitis C virus genotypes 1, 3 or 4 Data from a viral kinetic study showed a reduction in HCV RNA after seven days of dosing 4/24/13 Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

company stock symbols can be found in the stock report located on the last two pages of this issue

company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

company stock symbols can be found in the stock report located on the last two pages of this issue

bone-building synthetic peptide analogue Osteoporosis Completed enrollment for its pivotal Phase III study 3/13/13 Repros Therapeutics Inc. (The Woodlands, Texas) Androxal Enclomiphene Hypogonadism Pivotal study hit both of its primary endpoints – testosterone and sperm count 3/29/13 R-Tech Ueno (Tokyo) Unoprostone Ophthalmic solution Retinitis pigmentosa Began patient enrollment in a Phase III study 3/19/13 Notes: Public biotech company stock symbols can be found in the stock report located on

company stock symbols can be found in the stock report located on the last two pages of this issue

Now that its underwriter has exercised an option to purchase an additional $1.45 million in company stock, Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., is well situated to move ahead with its pipeline of compounded drug formulations based on its Accudel drug delivery technology, including Impracor, a Phase III pain candidate designed to deliver ketoprofen through the skin directly to underlying tissues

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

1% 2/5/13 Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

company stock symbols can be found in the stock report located on the last two pages of this issue

2/6/13 Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue